SCHEMBL4327263

SCHEMBL4327263

Cc1csc(NC(=O)c2ccccc2/C=C/c2n[nH]c3ccccc23)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.56
NPC1 O15118 10/20 0.54
RAB9A P51151 10/20 0.54
HPGD P15428 5/20 0.54
ALDH1A1 P00352 3/20 0.54
HTT P42858 2/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
TP53 P04637 1/20 0.54
GAA P10253 1/20 0.54
HSD17B10 Q99714 1/20 0.54
RCE1 Q9Y256 1/20 0.54
KMT2A Q03164 4/20 0.48
MEN1 O00255 3/20 0.48
MAPT P10636 2/20 0.48
LMNA P02545 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
PKM P14618 1/20 0.47
RECQL P46063 2/20 0.46
MAPK1 P28482 1/20 0.46
POLB P06746 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4327272 1.00 KDM4E (0.56) KDM4ENPC1RAB9AHPGDALDH1A1
SCHEMBL4316596 0.81 TSHR (0.51) KDM4ENPC1RAB9AHPGDALDH1A1
SCHEMBL4313388 0.81 CYP1A2 (0.52) KDM4ENPC1RAB9AHPGDALDH1A1
SCHEMBL4313399 0.81 CYP1A2 (0.52) KDM4ENPC1RAB9AHPGDALDH1A1
SCHEMBL4316604 0.81 TSHR (0.51) KDM4ENPC1RAB9AHPGDALDH1A1
SCHEMBL4308050 0.79 FLT3 (0.58) KDM4ENPC1SMN1; SMN2
SCHEMBL4308053 0.79 FLT3 (0.58) KDM4ENPC1SMN1; SMN2
SCHEMBL12258302 0.79 CSNK2A1 (0.67) KDM4ENPC1RAB9AHPGDALDH1A1
SCHEMBL4313848 0.75 PARP1 (0.46) KDM4EHPGDALDH1A1HTTL3MBTL1
SCHEMBL4313841 0.75 PARP1 (0.46) KDM4EHPGDALDH1A1HTTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 US disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 KDM4E 1251/4885NPC1 2575/4885RAB9A 2711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.